thuốc tirzepatide Cảnh báo nguy cơ phụ

We should expect Novo Nordisk and Lilly to increase competitive intensity in 2025, while more markets will see head-on competition between the two as better supply allows semaglutide and tirzepatide to be launched in more countries

Angiotensin-converting enzyme inhibitorassociated elevations in serum creatinine: is this a cause for concern

REIMAGINE 3 was a 40-week efficacy and safety phase 3 trial of CagriSema 2.4 mg/2.4 mg and 1 mg/1 mg once-weekly versus placebo in 274 adults with type 2 diabetes as add-on to once-daily basal insulin with or without metformin

Is thyroid cancer curable with surgery, or can it come back